vs

Side-by-side financial comparison of AIR LEASE CORP (AL) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $140.8M, roughly 1.1× AIR LEASE CORP). AIR LEASE CORP runs the higher net margin — 128.5% vs -5.5%, a 134.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 90.4%). AIR LEASE CORP produced more free cash flow last quarter ($342.1M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 69.6%).

Air Lease Corporation (ALC) is an American aircraft leasing company founded in 2010 and headed by Steven F. Udvar-Házy. Air Lease purchases new commercial aircraft through direct orders from Boeing, Airbus, Embraer and ATR, and leases them to its airline customers worldwide through specialized aircraft leasing and financing.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

AL vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.1× larger
TARS
$151.7M
$140.8M
AL
Growing faster (revenue YoY)
TARS
TARS
+37.9% gap
TARS
128.4%
90.4%
AL
Higher net margin
AL
AL
134.0% more per $
AL
128.5%
-5.5%
TARS
More free cash flow
AL
AL
$329.2M more FCF
AL
$342.1M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
69.6%
AL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AL
AL
TARS
TARS
Revenue
$140.8M
$151.7M
Net Profit
$180.9M
$-8.4M
Gross Margin
Operating Margin
-5.3%
Net Margin
128.5%
-5.5%
Revenue YoY
90.4%
128.4%
Net Profit YoY
60.2%
63.8%
EPS (diluted)
$1.49
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AL
AL
TARS
TARS
Q4 25
$140.8M
$151.7M
Q3 25
$44.5M
$118.7M
Q2 25
$53.0M
$102.7M
Q1 25
$92.9M
$78.3M
Q4 24
$74.0M
$66.4M
Q3 24
$65.0M
$48.1M
Q2 24
$57.8M
$40.8M
Q1 24
$49.0M
$27.6M
Net Profit
AL
AL
TARS
TARS
Q4 25
$180.9M
$-8.4M
Q3 25
$146.5M
$-12.6M
Q2 25
$385.2M
$-20.3M
Q1 25
$375.8M
$-25.1M
Q4 24
$112.9M
$-23.1M
Q3 24
$104.0M
$-23.4M
Q2 24
$102.9M
$-33.3M
Q1 24
$107.9M
$-35.7M
Operating Margin
AL
AL
TARS
TARS
Q4 25
-5.3%
Q3 25
-12.2%
Q2 25
-21.6%
Q1 25
-33.5%
Q4 24
-36.8%
Q3 24
-52.3%
Q2 24
-81.6%
Q1 24
-136.5%
Net Margin
AL
AL
TARS
TARS
Q4 25
128.5%
-5.5%
Q3 25
329.2%
-10.6%
Q2 25
726.9%
-19.8%
Q1 25
404.5%
-32.1%
Q4 24
152.7%
-34.8%
Q3 24
160.0%
-48.7%
Q2 24
178.2%
-81.6%
Q1 24
220.2%
-129.4%
EPS (diluted)
AL
AL
TARS
TARS
Q4 25
$1.49
$-0.17
Q3 25
$1.21
$-0.30
Q2 25
$3.33
$-0.48
Q1 25
$3.26
$-0.64
Q4 24
$0.83
$-0.57
Q3 24
$0.82
$-0.61
Q2 24
$0.81
$-0.88
Q1 24
$0.87
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AL
AL
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$466.4M
$417.3M
Total DebtLower is stronger
$19.7B
$72.4M
Stockholders' EquityBook value
$8.5B
$343.4M
Total Assets
$32.9B
$562.2M
Debt / EquityLower = less leverage
2.33×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AL
AL
TARS
TARS
Q4 25
$466.4M
$417.3M
Q3 25
$452.2M
$401.8M
Q2 25
$454.8M
$381.1M
Q1 25
$456.6M
$407.9M
Q4 24
$472.6M
$291.4M
Q3 24
$460.8M
$317.0M
Q2 24
$454.1M
$323.6M
Q1 24
$554.4M
$298.5M
Total Debt
AL
AL
TARS
TARS
Q4 25
$19.7B
$72.4M
Q3 25
$20.2B
$72.3M
Q2 25
$20.3B
$72.1M
Q1 25
$19.9B
$72.0M
Q4 24
$20.2B
$71.8M
Q3 24
$20.2B
$71.7M
Q2 24
$19.7B
$71.6M
Q1 24
$19.5B
$29.9M
Stockholders' Equity
AL
AL
TARS
TARS
Q4 25
$8.5B
$343.4M
Q3 25
$8.3B
$335.1M
Q2 25
$8.2B
$332.6M
Q1 25
$7.9B
$342.5M
Q4 24
$7.5B
$224.5M
Q3 24
$7.7B
$237.5M
Q2 24
$7.3B
$252.2M
Q1 24
$7.2B
$275.2M
Total Assets
AL
AL
TARS
TARS
Q4 25
$32.9B
$562.2M
Q3 25
$33.4B
$534.6M
Q2 25
$33.3B
$495.0M
Q1 25
$32.4B
$500.8M
Q4 24
$32.3B
$377.0M
Q3 24
$32.2B
$376.3M
Q2 24
$31.0B
$376.8M
Q1 24
$30.9B
$349.3M
Debt / Equity
AL
AL
TARS
TARS
Q4 25
2.33×
0.21×
Q3 25
2.42×
0.22×
Q2 25
2.47×
0.22×
Q1 25
2.53×
0.21×
Q4 24
2.68×
0.32×
Q3 24
2.63×
0.30×
Q2 24
2.69×
0.28×
Q1 24
2.69×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AL
AL
TARS
TARS
Operating Cash FlowLast quarter
$414.1M
$19.3M
Free Cash FlowOCF − Capex
$342.1M
$13.0M
FCF MarginFCF / Revenue
242.9%
8.6%
Capex IntensityCapex / Revenue
51.1%
4.2%
Cash ConversionOCF / Net Profit
2.29×
TTM Free Cash FlowTrailing 4 quarters
$1.5B
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AL
AL
TARS
TARS
Q4 25
$414.1M
$19.3M
Q3 25
$458.6M
$18.3M
Q2 25
$473.6M
$-29.4M
Q1 25
$388.3M
$-20.7M
Q4 24
$430.0M
$-22.2M
Q3 24
$461.9M
$-8.7M
Q2 24
$413.8M
$-14.4M
Q1 24
$371.3M
$-37.8M
Free Cash Flow
AL
AL
TARS
TARS
Q4 25
$342.1M
$13.0M
Q3 25
$412.3M
$16.3M
Q2 25
$427.1M
$-30.4M
Q1 25
$315.5M
$-21.2M
Q4 24
$326.8M
$-22.3M
Q3 24
$369.8M
$-8.9M
Q2 24
$346.4M
$-15.4M
Q1 24
$246.8M
$-38.0M
FCF Margin
AL
AL
TARS
TARS
Q4 25
242.9%
8.6%
Q3 25
926.6%
13.8%
Q2 25
806.0%
-29.6%
Q1 25
339.5%
-27.1%
Q4 24
441.8%
-33.5%
Q3 24
569.1%
-18.6%
Q2 24
599.5%
-37.8%
Q1 24
503.8%
-137.5%
Capex Intensity
AL
AL
TARS
TARS
Q4 25
51.1%
4.2%
Q3 25
104.1%
1.6%
Q2 25
87.8%
1.0%
Q1 25
78.4%
0.8%
Q4 24
139.6%
0.1%
Q3 24
141.7%
0.6%
Q2 24
116.7%
2.5%
Q1 24
254.3%
0.6%
Cash Conversion
AL
AL
TARS
TARS
Q4 25
2.29×
Q3 25
3.13×
Q2 25
1.23×
Q1 25
1.03×
Q4 24
3.81×
Q3 24
4.44×
Q2 24
4.02×
Q1 24
3.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons